Evaluation of tryptophan-aspartic acid repeat-containing protein 34 as a novel tumor-suppressor molecule in human oral cancer.

Autor: Yamamoto JI; Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba, Japan., Kasamatsu A; Department of Dentistry and Oral-Maxillofacial Surgery, Chiba University Hospital, Chiba, Japan. Electronic address: kasamatsua@faculty.chiba-u.jp., Okubo Y; Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba, Japan., Nakashima D; Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba, Japan., Fushimi K; Division of Oral Surgery, Eastern Chiba Medical Center, Chiba, Japan., Minakawa Y; Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba, Japan; Division of Dentistry, Chiba Prefectural Sawara Hospital, Chiba, Japan., Kasama H; Division of Oral Surgery, Eastern Chiba Medical Center, Chiba, Japan., Shiiba M; Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan., Tanzawa H; Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba, Japan; Department of Dentistry and Oral-Maxillofacial Surgery, Chiba University Hospital, Chiba, Japan., Uzawa K; Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba, Japan; Department of Dentistry and Oral-Maxillofacial Surgery, Chiba University Hospital, Chiba, Japan.
Jazyk: angličtina
Zdroj: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2018 Jan 22; Vol. 495 (4), pp. 2469-2474. Date of Electronic Publication: 2017 Dec 24.
DOI: 10.1016/j.bbrc.2017.12.138
Abstrakt: Tryptophan-aspartic acid (WD) repeat-containing protein 34 (WDR34), one of the WDR protein superfamilies with five WD40 domains, inhibits a transforming growth factor-beta (TGF-β) activated kinase 1 (TAK1)-associated NF-κB activation pathway. Nevertheless, little is known about the roles of WDR34 in cancer. The current study sought to elucidate the clinical relevance of WDRsfb34 in oral squamous cell carcinoma (OSCC). We found WDR34 down-regulation in OSCCs compared with normal control tissues using real-time quantitative reverse transcription-polymerase chain reaction, immunoblotting, and immunohistochemistry. Models of overexpression of WDR34 (oeWDR34) showed depressed cellular growth through cell-cycle arrest at the G1 phase. To investigate the inhibitory function of WDR34, we challenged oeWDR34 cells with interleukin (IL)-1, a ligand for activation of the TAK1-NF-κB pathway and assessed the expression of a target gene of the pathway. oeWDR34 strongly inhibited IL-6 expression, which is closely related to tumoral growth, compared with control cells, suggesting that WDR34 would be a critical molecule for control of tumoral progression. In addition to the in vitro experiments, WDR34 negativity was correlated with tumoral growth of OSCCs. Our findings suggested that WDR34 inhibits OSCC progression and might be a potential tumor-suppressor molecule in OSCCs.
(Copyright © 2017 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: